Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Should You Buy Cullen/Frost Bankers, Inc. (CFR)?

Page 1 of 2

In the financial world, there are a multitude of gauges investors can use to watch Mr. Market. A couple of the best are hedge fund and insider trading sentiment. At Insider Monkey, our studies have shown that, historically, those who follow the top picks of the elite money managers can beat the market by a significant margin (see just how much).

Just as key, positive insider trading sentiment is another way to analyze the investments you’re interested in. As the old adage goes: there are many incentives for an executive to cut shares of his or her company, but just one, very obvious reason why they would behave bullishly. Plenty of academic studies have demonstrated the impressive potential of this tactic if you understand where to look (learn more here).

Now that that’s out of the way, we’re going to analyze the latest info for Cullen/Frost Bankers, Inc. (NYSE:CFR).

Hedge fund activity in Cullen/Frost Bankers, Inc. (NYSE:CFR)

In preparation for the third quarter, a total of 10 of the hedge funds we track were bullish in this stock, a change of 43% from the previous quarter. With hedgies’ positions undergoing their usual ebb and flow, there exists an “upper tier” of key hedge fund managers who were increasing their holdings substantially.

Cullen/Frost Bankers, Inc. (NYSE:CFR)Out of the hedge funds we follow, Martin Whitman’s Third Avenue Management had the biggest position in Cullen/Frost Bankers, Inc. (NYSE:CFR), worth close to $19.5 million, comprising 0.4% of its total 13F portfolio. On Third Avenue Management’s heels is Ken Griffin of Citadel Investment Group, with a $15.2 million position; less than 0.1%% of its 13F portfolio is allocated to the stock. Other hedgies that hold long positions include Jim Simons’s Renaissance Technologies, Dmitry Balyasny’s Balyasny Asset Management and Ken Gray and Steve Walsh’s Bryn Mawr Capital.

Now, particular hedge funds were breaking ground themselves. Third Avenue Management, managed by Martin Whitman, established the biggest position in Cullen/Frost Bankers, Inc. (NYSE:CFR). Third Avenue Management had 19.5 million invested in the company at the end of the quarter. Ken Griffin’s Citadel Investment Group also made a $15.2 million investment in the stock during the quarter. The other funds with brand new CFR positions are Jim Simons’s Renaissance Technologies, Dmitry Balyasny’s Balyasny Asset Management, and Ken Gray and Steve Walsh’s Bryn Mawr Capital.

What have insiders been doing with Cullen/Frost Bankers, Inc. (NYSE:CFR)?

Insider buying made by high-level executives is particularly usable when the company we’re looking at has experienced transactions within the past half-year. Over the latest half-year time period, Cullen/Frost Bankers, Inc. (NYSE:CFR) has seen zero unique insiders purchasing, and zero insider sales (see the details of insider trades here).

We’ll go over the relationship between both of these indicators in other stocks similar to Cullen/Frost Bankers, Inc. (NYSE:CFR). These stocks are Texas Capital Bancshares Inc (NASDAQ:TCBI), UMB Financial Corporation (NASDAQ:UMBF), Prosperity Bancshares, Inc. (NYSE:PB), BOK Financial Corporation (NASDAQ:BOKF), and Commerce Bancshares, Inc. (NASDAQ:CBSH). All of these stocks are in the regional – southwest banks industry and their market caps are closest to CFR’s market cap.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!